These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 39337607)

  • 1. Semen sEV tRF-Based Models Increase Non-Invasive Prediction Accuracy of Clinically Significant Prostate Cancer among Patients with Moderately Altered PSA Levels.
    Ferre-Giraldo A; Castells M; Sánchez-Herrero JF; López-Rodrigo O; de Rocco-Ponce M; Bassas L; Vigués F; Sumoy L; Larriba S
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis.
    Barceló M; Castells M; Bassas L; Vigués F; Larriba S
    Sci Rep; 2019 Sep; 9(1):13772. PubMed ID: 31551516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Extracellular Vesicle Isolation Methods on Downstream Mirna Analysis in Semen: A Comparative Study.
    Mercadal M; Herrero C; López-Rodrigo O; Castells M; de la Fuente A; Vigués F; Bassas L; Larriba S
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32824915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
    Tosoian JJ; Zhang Y; Xiao L; Xie C; Samora NL; Niknafs YS; Chopra Z; Siddiqui J; Zheng H; Herron G; Vaishampayan N; Robinson HS; Arivoli K; Trock BJ; Ross AE; Morgan TM; Palapattu GS; Salami SS; Kunju LP; Tomlins SA; Sokoll LJ; Chan DW; Srivastava S; Feng Z; Sanda MG; Zheng Y; Wei JT; Chinnaiyan AM;
    JAMA Oncol; 2024 Jun; 10(6):726-736. PubMed ID: 38635241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
    Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
    Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry.
    Biggs CN; Siddiqui KM; Al-Zahrani AA; Pardhan S; Brett SI; Guo QQ; Yang J; Wolf P; Power NE; Durfee PN; MacMillan CD; Townson JL; Brinker JC; Fleshner NE; Izawa JI; Chambers AF; Chin JL; Leong HS
    Oncotarget; 2016 Feb; 7(8):8839-49. PubMed ID: 26814433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
    Omri N; Kamil M; Alexander K; Alexander K; Edmond S; Ariel Z; David K; Gilad AE; Azik H
    Prostate; 2020 Dec; 80(16):1444-1449. PubMed ID: 32970856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
    Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
    Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of the main PSA glycoforms in aggressive prostate cancer.
    Gratacós-Mulleras A; Duran A; Asadi Shehni A; Ferrer-Batallé M; Ramírez M; Comet J; de Llorens R; Saldova R; Llop E; Peracaula R
    Sci Rep; 2020 Nov; 10(1):18974. PubMed ID: 33149259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
    Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
    Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
    Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
    Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
    Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
    Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.